GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that a notice that a Clinical Use Patent for the drug candidate arfolitixorin will be approved in Europe. The patent covers a dose regimen for treating solid tumors, such as colorectal, stomach, breast and liver cancer and expires in 2038.
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announced on 19 March 2021 that the independent Data Safety and Monitoring Board (iDSMB) has recommended continuation of the global Phase III AGENT study with 440 patients, in accordance with the study design for the drug candidate, arfolitixorin. In connection with this, Isofol invites investors, analysts and media to a conference call and webcast on March 22, 2021 at 14:00 (CET).
GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that the independent Data Safety and Monitoring Board (iDSMB) has recommended continuation of the global Phase III AGENT study with 440 patients, in accordance with the study design for the drug candidate, arfolitixorin. Isofol expects the top line results for the AGENT study to be available during H1 2022.
The approved abstract for the congress American Association for Cancer Research (AACR) 2021 has been published on their website. The congress will take place during April 10-15, 2021 and the poster will be available on April 10. Link to the abstract >> When the poster will be presented at AACR, it will also be published …
